BR112014014308A2 - anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa - Google Patents

anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa

Info

Publication number
BR112014014308A2
BR112014014308A2 BR112014014308A BR112014014308A BR112014014308A2 BR 112014014308 A2 BR112014014308 A2 BR 112014014308A2 BR 112014014308 A BR112014014308 A BR 112014014308A BR 112014014308 A BR112014014308 A BR 112014014308A BR 112014014308 A2 BR112014014308 A2 BR 112014014308A2
Authority
BR
Brazil
Prior art keywords
dhea
active ingredient
release
menopause
women
Prior art date
Application number
BR112014014308A
Other languages
English (en)
Inventor
Ariel Fuentes García Frans
Del Carmen Beltrán Apablaza Marianela
Chen Shu-Chen
Original Assignee
Laboratorios Andrómaco S A
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Andrómaco S A, Univ Chile filed Critical Laboratorios Andrómaco S A
Publication of BR112014014308A2 publication Critical patent/BR112014014308A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

resumo “anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa” a invenção refere-se a um anel vaginal de liberação controlada que inclui a dehidroepiandrosterona (dhea), sulfato de dehidroepiandrosterona (dhea-s) ou um sal farmaceuticamente aceitável dos mesmos como um princípio ativo e, opcionalmente, um agente modulador da liberação do princípio ativo, em que a quantidade do princípio ativo é entre 1% em peso e 32% em peso em relação ao peso total da formulação, e o agente modulador é selecionado entre: polivinilpirrolidona k-30, lactose, celulose micro cristalina e lauril sulfato de sódio. o anel vaginal da presente invenção pode ser utilizado para aumentar a reserva do ovário em mulheres, para ser utilizado como um medicamento em programas de reprodução assistida e para aliviar os sintomas associados com a menopausa, tais como sintomas de atrofia vulvar e vaginal e a disfunção sexual na pós-menopausa.
BR112014014308A 2011-12-29 2011-12-29 anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa BR112014014308A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056023 WO2013098592A1 (es) 2011-12-29 2011-12-29 Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia

Publications (1)

Publication Number Publication Date
BR112014014308A2 true BR112014014308A2 (pt) 2017-06-13

Family

ID=48696405

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014308A BR112014014308A2 (pt) 2011-12-29 2011-12-29 anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa

Country Status (12)

Country Link
US (1) US9066956B2 (pt)
EP (1) EP2799042A4 (pt)
JP (1) JP5887424B2 (pt)
KR (1) KR101622861B1 (pt)
CN (1) CN104271084B (pt)
BR (1) BR112014014308A2 (pt)
CA (1) CA2860133C (pt)
CR (1) CR20140270A (pt)
EA (1) EA027633B1 (pt)
MX (1) MX350336B (pt)
NI (1) NI201400067A (pt)
WO (1) WO2013098592A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
CN108537785B (zh) * 2018-04-04 2021-04-30 北京大学人民医院 一种子宫超声微蠕动视频处理方法
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
AU2020397648B2 (en) 2019-12-06 2022-03-24 Prathima Chowdary Sustained release estrogen vaginal ring pessary for treatment of atrophy, cystitis and uterovaginal prolapse

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100541C (zh) 1993-01-19 2003-02-05 恩多研究公司 脱氢表雄酮的治疗用途和传送系统
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ES2098193B1 (es) 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
EP1350541A1 (de) 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
US20060089308A1 (en) 2004-10-26 2006-04-27 American Infertility Of New York Method of improving ovulation induction using an androgen such as dehydroepiandrosterone
US9375436B2 (en) 2004-10-26 2016-06-28 Norbert Gleicher Androgen treatment in females
US8067400B2 (en) 2004-10-26 2011-11-29 American Infertility Of New York Androgen treatment in females
US8501719B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US8501718B2 (en) 2005-11-08 2013-08-06 American Infertility Of New York Androgen treatment in females
US7615544B2 (en) 2004-10-26 2009-11-10 American Infertility Of New York Method of improving cumulative embryo score and quantity of fertilized oocytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone
WO2007070067A1 (en) * 2005-12-16 2007-06-21 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
CN105581976A (zh) * 2007-06-26 2016-05-18 沃纳奇尔科特有限责任公司 用于递送大分子和水溶性药物的阴道内药物递送装置
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
US9066956B2 (en) 2015-06-30
JP2015506933A (ja) 2015-03-05
CR20140270A (es) 2014-10-31
CA2860133C (en) 2016-10-11
US20150004214A1 (en) 2015-01-01
KR101622861B1 (ko) 2016-05-19
MX350336B (es) 2017-09-04
JP5887424B2 (ja) 2016-03-16
EP2799042A4 (en) 2015-02-11
MX2014007957A (es) 2015-11-06
CA2860133A1 (en) 2013-07-04
EA201491165A1 (ru) 2014-12-30
WO2013098592A1 (es) 2013-07-04
EA027633B1 (ru) 2017-08-31
CN104271084B (zh) 2017-03-01
NI201400067A (es) 2016-02-15
EP2799042A1 (en) 2014-11-05
KR20140109987A (ko) 2014-09-16
CN104271084A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
Friend et al. Multipurpose prevention technologies: products in development
BR112014014308A2 (pt) anel vaginal que inclui dhea ou sulfato de dhea e, opcionalmente, um agente para modular a liberação do princípio ativo, que pode ser usado para aumentar a reserva ovariana nas mulheres e para aliviar os sintomas associados à menopausa
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
CN101390854A (zh) 一种含有利鲁唑的药用组合物
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
PE20130524A1 (es) Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
JP2018527305A5 (pt)
CU20200074A7 (es) Composiciones que comprenden un componente de estetrol útiles para aliviar síntomas asociados a la menopausia
BR112012032189A2 (pt) métodos de tratamento ou prevenção de doenças relacionadas com estrogênio
BR112014018393A8 (pt) Composição farmacêutica adequada para liberação ocular de um esteroide e uso da mesma para a fabricação de um medicamento para tratar uma doença oftálmica
JP2020504129A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
BR112016013500B8 (pt) composto, composição farmacêutica, e, uso de um composto
White et al. Effects of naproxcinod on blood pressure in patients with osteoarthritis
Chan et al. Pharmacological treatment approaches to difficult‐to‐treat depression
BR112023003317A2 (pt) Composições e métodos para o tratamento da colangite biliar primária
CO7151514A2 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia.
DOP2014000143A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
AR088704A1 (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberacion del principio activo, util para aumentar la reserva ovarica en mujeres y para aliviar sintomas asociados a la menopausia
ITFI20120128A1 (it) Formulazioni per la preparazione di compresse per uso orale a rilascio immediato contenenti mifepristone a basso dosaggio per il trattamento di endometriosi, compresse così ottenute e loro processo di preparazione.
BR112021025409A2 (pt) Composição livre de androgênio esteroidal
ECSP14008170A (es) Anillo vaginal que comprende dhea o dhea sulfato y opcionalmente un agente modulador de la liberación del principio activo, útil para aumentar la reserva ovárica en mujeres y para aliviar síntomas asociados a la menopausia
Piche et al. Treatment of Delayed Ejaculation

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]